Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Review of the latest abstracts from the COU-AA-302 trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 31.01.14
Views: 3956

Dr Chris Parker and Prof Stephane Oudard

At an expert to expert discussion at ASCO GU congress 2014, Dr Chris Parker from The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom is joined by Professor Stephane Oudard from Georges Pompidou Hospital, Paris, France to discuss the latest clinical strategies used to treat metastatic castration-resistant prostate cancer (mCRPC).

They cover:

- The impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: results from COU-AA-302

- The response to androgen signaling-directed therapy after treatment with abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post-hoc analysis of study

- The association of alkaline phosphatase with clinical outcomes in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: results from COU-AA-302

- Data from the PREVAIL trial


The discussion looks at the potential future of the evolving treatment options in CRPC in terms of:

- Understanding clinical strategies to overcome androgen resistance
- Understanding what treatment options are available for patients with CRPC
- Determining the correct sequence for the use of newly available drugs for the management of CRPC
- Identifying patient sub-groups that can optimally benefit from new treatment approaches


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).


Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation